Biopôle Lausanne’s Post

🌟 Ashibiotech Raises $40M in Seed and Series A Financing! 🚀 We're thrilled to announce that Ashibiotech, a leading innovator in the biotech industry, has successfully raised $40 million in Seed and Series A funding. This significant investment will fuel their mission to revolutionise healthcare with cutting-edge biotechnological solutions. 💡 Key Highlights: -Funding Details: The $40 million raised includes contributions from top-tier investors, demonstrating strong confidence in Ashibiotech's vision and potential. -Innovation Focus: Ashibiotech is committed to advancing healthcare with breakthrough technologies that promise to make a substantial impact on patient outcomes. -Growth and Expansion: This funding will accelerate R&D efforts, enhance product development, and support expansion into new markets. With this fresh capital, Ashibiotech is poised to drive innovation and bring transformative biotech solutions to the global healthcare landscape. 🌍 #Biotech #HealthcareInnovation #Funding #StartupSuccess #Ashibiotech #SeriesAFunding #SeedFunding #TechNews #Innovation #HealthcareRevolution

It was a pleasure to host the 2nd Life Science Venture Capital Impact Day mid-April at Trill Impact offices in Stockholm. It was energizing to exchange views with leading European and US #venturecapital firms on the role of #Impactinvesting and #ESG in the early-stage life science companies. Here are my takeaways: - ESG reporting was challenged as a box-ticking exercise. How can we make it into the value adding tool it is intended to be? Collaboration between VC firms is ongoing, and I believe we will see the fruition of the work in the coming years - Impact Investing in Life Science has different definition for different VC funds and is evolving. By focusing on our common denominators, we will increase the opportunity to collaborate and tell the story of the impact we are creating together  Silva Deželan, PhD, Merijn Klaassen, Robert Carroll, Beatriz Gandarias Calzada, Hannah Maunder, Roger Franklin, Noella de Bermingham, Kabeer Aziz,Patrik Sobocki (MSc, PhD), Anna Ljungdahl, Dr. Stephanie Mooij, Sarah Lafaye, Bobby Soni, Diana Torgersen, Hugues Bultot, Joachim Nahem, Eleanor Price, Dustin Zielinski, Ingrid Beyer, Linn Hege Aune, Ane Tolnes Haugdal, Johanneke Maenhout, Jan Ståhlberg, Nina Rawal,Niclas During, Ånirban Bhattachariya, PhD, MBA,

We are celebrating! biosimulytics has successfully completed our 1-year review for the prestigious #EICAccelerator Programme! For those who may not be familiar, the European Innovation Council (EIC) is an initiative by the European Commission aimed at supporting high-risk, high-impact innovations. The EIC Accelerator Programme is one of the most selective and competitive funding programmes under Horizon Europe and is designed to support the most innovative start-ups and SMEs with breakthrough products, services, and business models that have the potential to create new markets or disrupt existing ones. The 1-year review is an in-depth evaluation that includes: 🔹 Progress Assessment: Evaluating the milestones achieved against our initial project plan and assessing our technical and commercial progress. 🔹 Financial Review: Examining our financial management and expenditure of the grant funds to ensure they have been used appropriately and effectively. 🔹 Impact Evaluation: Analyzing our project’s impact on the market and its potential to create new markets or disrupt existing ones, as well as its societal and economic benefits. 🔹 Future Plans: Assessing our plans for the next phases of development and commercialization and evaluating our strategies for scaling up and achieving long-term sustainability. This milestone is a testament to the impact of our platform thanks to the hard work and dedication of our team. We are beyond excited about the future and immensely grateful for the support from the EIC Accelerator. A huge thank you to our dedicated team, partners, and supporters who have been with us on this incredible journey! #Innovation #Milestone #Growth #InvestInInnovation #Biotech #HealthTech #DeepTech #StartUp European Innovation Council and SMEs Executive Agency (EISMEA) NovaUCD Viridien

Biotech and Cleantech sectors are on the rise! 🚀🌿 Despite the market slump in recent years, the signs of recovery keep on coming... - In Q2 2024, the biotech sector saw a significant rebound, with total deal value surpassing that of 2023. - The average capital raised per follow-on round increased by 47% compared to 2023 = growing investor confidence 💰🌟 - The global startup funding in Q2 2024 reached $79 billion, up 12% from Q2 2023, with much of that coming from the biotech sector 📈 Here are some (of many!) exciting funding milestones that deserve a shout-out: 1️⃣ LabGenius raised £35 million in a Series B round, led by M Ventures, to advance their ML-driven drug discovery platform. Congrats to James Field and the team! 🧬 2️⃣ Onego Bio secured €14 million to scale their animal-free egg protein, Bioalbumen®. Kudos to Maija Itkonen and the team for pushing the boundaries of sustainable food tech! 🥚 3️⃣ RebrAIn completed a €3.7 million seed round, led by Karista, enhancing their precision neurosurgery solutions. Big shoutout to David C. and the team! 🧠 4️⃣ AmphiStar raised €6 million to expand production of eco-friendly biosurfactants. Congratulations to Pierre-Franck VALENTIN and the AmphiStar team for their green innovations! 🌿 5️⃣ Insempra completed a $20 million Series A round to develop sustainable, bio-based ingredients for food and cosmetics. Nice work, Jens Klein and the Insempra team for driving innovation in biomanufacturing! 🌿🔬 Seeing success stories like this really is very promising for what's to come... Onwards and upwards!! #Biotech #Funding #Innovation #Sustainability #HealthTech

I was delighted to co-chair a Biotechnology Investment roundtable with Minister Andrew Griffith MP at No10 last week, discussing the pivotal role the UK plays in global R&D, supply chains, evidence development, and value creation 🔬 We are home to 1 in 3 of all the biotech startups founded in Europe over the last decade, and in 2023, the UK upheld its position as Europe's leading biotech hub, contributing to 41% of the total venture capital raised across the continent 🥇 This opportunity allowed us to collaborate with specialist venture capital investors, institutional investors and sector leaders to discuss biotech investment. We're continuing to find solutions for sustainable resource management, enabling innovation in healthcare, and tackling the challenges of decarbonisation as we aim to reach net zero 📈 🌳 The UK is one of the best places in the world to invest!

After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one, venture investment appears to have stabilized at levels seen prior to a pandemic-era spike. Data presented by the Biotechnology Innovation Organization at the group’s annual meeting this week in San Diego showed private drug companies in the U.S. raised $3.8 billion during the first quarter.... Venture capital firms are also active in raising cash, reloading for new investment in the sector. Several new groups have launched this year, including Regeneron’s venture arm and Goldman Sachs’ first life sciences fund, which raised $650 million. Established investors are busy, too: ARCH Venture Partners outlined plans in February to raise $3 billion, while Canaan Partners X LLC recently added $100 million to its 13th fund.... #investing #investment #IPO #MergersandAcquisitions #funding #financing #biotech #biotechnology #returningtonormal #capitaldeployment Biotechnology Innovation Organization #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #lifesciences #lifescience #BIO2024

We are pleased to share the Extend 2023 #results, thrilled to highlight the transformative journey in #biotech #innovation, underscored by strategic collaborations that define our mission. Strategic Collaborations: In our pursuit of valorising research results, Extend has forged impactful partnerships with eight prominent universities and research centres in Italy, including esteemed institutions such as Ospedale San Raffaele, Università degli Studi di Milano, Università degli Studi di Padova, Università di Trento, Università degli Studi di Firenze, Università degli Studi di Modena e Reggio Emilia, Sapienza Università di Roma and the Apulia regional district through BINP - Boosting Innovation in Poliba. These collaborations signify our dedication to creating an environment conducive to pioneering advancements. Corporate Alliance: Evotec as scientific partner with a dedicated Expert in Residence, has played a pivotal role in driving the success of our scouting and due diligence activities. Alongside Angelini Ventures have significantly reinforced Extend's foundation through their strategic investment, amplifying our capabilities to drive innovation forward. This collaboration further solidifies our commitment to seamlessly integrating academic and corporate expertise. Entrepreneurial Drive: In parallel, we have embraced the addition of two distinguished Entrepreneurs-in-Residence, enriching our team with diverse perspectives and profound #entrepreneurial #expertise. Investment Activity: In 2023 we analysed more than 130 projects, out of more than 200 projects received that led to 8 #strategic #investments in pioneering drug discovery projects. These initiatives represent the tangible impact of our commitment to advancing transformative innovations in the biotech landscape, offering potential new therapeutic approaches for patients. Indirect Investments Achievements: CDP Venture Capital SGR has expanded its footprint by investing in two new first time team/first time venture capital funds, Indaco Venture Partners and XGEN Venture SGR S.p.A., signalling our continued dedication to fostering a comprehensive and impactful approach to biotech innovation in Italy and globally. As we bask in the success of 2023, we look forward with immense excitement to what lies ahead in 2024. Anticipate ground-breaking advancements, continued collaboration with trailblazing partners, and the exploration of novel frontiers in biotech innovation. We extend our deepest gratitude to our stakeholders for shaping our narrative and invite you to stay tuned for more updates as we persist in our commitment to advancing transformative innovations in the biotech landscape.

Biotech Investor Preferences Shift - Companies Need to Walk Through Their Journey to Commercial Success Private biotech companies, even those in earlier stages, must have a compelling commercialization story to attract investor interest. Investors prefer backing companies with strong scientific foundations and robust clinical pipelines. They also increasingly expect companies to articulate a clear story about the unmet need in their target disease and the role their medicine will play. Describing the path to commercialization is crucial. This can be a challenging exercise, but companies are failing because they are not able to do this effectively. Fundraising Best Practices (abbreviated checklist) - Planning and Strategy: Ø Develop Multiple Plans: Always have a Plan B and Plan C ready, especially for clinical pathways. Ø Credible Commercialization Pathway: Ensure a clear and credible commercialization pathway. Ø Clear Storytelling: Companies often fail due to unclear communication of the unmet need and the role of their medicine. Simplify for investors but add nuance for disease experts. Communication and Storytelling: Ø Tailor Communication: Differentiate your messaging for investors (simple, clear) versus disease experts (nuanced, detailed). Ø Dual Presentations: Have two versions of your presentation – one scientific and one financial. Ø Highlight Commercial Opportunity Early: Emphasize the commercial potential early in the process, not just the science. Ø Evolve Your Story: Continuously update and adapt your story as your project and the external environment evolve. Team and Capabilities: Ø Highlight Capabilities: Clearly articulate why your team is the right one and what unique skills they bring. Ø Focus on Unfair Advantage: Identify and communicate your company's unique advantages and strengths. Ø Capabilities Across Functions: Highlight capabilities in critical areas like CMC (Chemistry, Manufacturing, and Controls), supply chain management, and other operational aspects. Commercial and Market Considerations: Ø Early Market Planning: Integrate commercial thinking from the preclinical stage. Ø Scenario Planning: Conduct scenario planning to understand how your product will compete in the market. Ø Understand the Market: Research the current therapeutic market, treatment guidelines, reimbursement decisions, and competition. Safety and Manufacturing: Ø Focus on Safety and Manufacturing: Address safety concerns and manufacturing capabilities as top priorities. Long-term Vision and Adaptability: Ø Adapt to Changes: Be ready to adapt your story and strategy as external circumstances and market trends change.   #privatebiotechfundraising #fundraising #biotech https://lnkd.in/eg8a9XWW

Come watch Asclepii pitch!

🥳Now, it’s time to meet our #IamPitching competition participants. In this post, we introduce ELBIOTECH Sp. z o.o. from Poland. 🚀ELBIOTECH pioneers ultra-fast sterilization technology from Warsaw, protecting porous materials with a patented device that disinfects without damage. ➡️ https://lnkd.in/ddQDNA38 Click on the video to open it on YouTube then hit the thumbs-up button on the startup’s video pitch to support them in winning special prizes in the program. 🏆🥇 The organisers: OUVC - Venture Capital & Venture Studio, Accelpoint, Insane Business Ideas, Rivne IT Cluster  The project is co-financed by the Governments of Czechia, Hungary, Poland, and Slovakia through Visegrad Grants from the International Visegrad Fund. The mission of the fund is to advance ideas for sustainable regional cooperation in Central Europe. #InnovationJourney #ProfessionalDevelopment #Entrepreneurship #MentorshipMagic #VisegradFund